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ABsTRACT
High levels of growth hormone accelerate mitosis rate but decrease the apoptosis process in its target organs. 
These events might cause the initiation of different cancer types. Thus, the main aims of this study were assessing the 
effects of short term growth hormone administration and resistance training on the histopathology and detection of 
the BRAF-V600E mutation in the thyroid tissue of male Rattus norvegicus brown rats. Thirty-two rats were randomly 
divided into four groups. After 8 weeks of the experiment (i.m), thyroid tissue and blood samples of saline (CS), 
resistance training+saline (RS), growth hormone (2 mg/kg) (GI) and resistance training+growth hormone (2 mg/kg) 
(RG) were taken to evaluate histopathology, the BRAF T1799A mutation of thyroid tissue, and circulating levels of 
IGF-1 and IGFBP-3. The protocol of training consisted of rats climbing a ladder while carrying weights (3 sets/5 reps). 
Microscopic evaluation of thyroid tissue did not show any histopathological changes, and there were no mutations 
in the studied region of the BRAF sequence. Serum IGF-1 concentration was significantly lower in the RS group 
than in other groups (P<0.05). However, serum IGFBP-3 concentration did not change significantly in the RS group. 
Moreover, serum IGF-1 and IGFBP-3 concentrations were significantly higher in the GI and RG groups than in the 
others (P<0.05). In conclusion, the decrement of serum IGF-1 concentration and IGF-1/IGFBP-3 ratio after resistance 
training might decrease the risk of cancer. Furthermore, short term growth hormone administration, with and without 
resistance training, might increase the risk of cancer through the high levels of serum IGF-1 concentration and IGF-1/
IGFBP-3 ratio in male rats. 
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introduction
Health science has faced major challenges in the 
management of mutation in all diseases. Nowadays, 
many hormonal drugs affect the thyroid system, 
and common therapeutic methods often result in 
unsatisfactory results. There is increasing interest 
in this topic, due to the overall increase in thyroid 
disorder in industrialized countries (PELLEGRITI 
et al., 2013), but there is still much to learn 
concerning the effect of hormonal therapy and 
training on the thyroid system. 
Growth hormone (GH) is secreted by the 
pituitary gland, which is controlled by hypothalamic 
hormones. Due to the frequency of GH receptors 
in practically all cells and tissues, GH induces 
a variety of actions in all cells (ALLARD and 
DUAN, 2018). One of the main actions of GH is 
stimulation of insulin growth factor-1 (IGF-1) 
and synthesis of its binding proteins. There are at 
least six types of IGF-Binding Proteins (IFGBPS) 
that transport IGFs in the blood and other fluids 
of the body to their receptors (IGF-1R). IGF-1 is 
transported primarily by IGFBP-3 which protect 
the IGF-1 from proteolytic degradation and extend 
its half-life. The amount of free IGF-1 in the 
blood is of great importance for cell proliferation. 
IGFBPS can oppose actions to IGF-1, partly by 
binding to IGF-1 and preventing it from attaching 
to its membrane receptors (ALLARD and DUAN, 
2018). The IGFBPS regulates IGFs’ bioavailability 
up to 50-fold higher than IGF-1R (GHANIPOOR-
SAMAMI et al., 2018). Some studies have indicated 
that high levels of IGF-1 concentration, low levels 
of IGFBP-3 concentration and/or increased IGF-1/
IGFBP-3 ratio are associated with an increased risk 
of several types of carcinoma (FENG et al., 2017; 
SOUBRY et al., 2012). It has been shown that both 
acute and chronic resistance exercise increases 
intramuscular IGF-1 levels (OGASAWARA et al., 
2013). Contrarily, the effects of resistance training 
on circulating IGF-1 and IGFBP-3 levels are 
inconsistent (ELIAKIM et al., 1998; NINDL et al., 
2004; NINDL et al., 2010; NISHIDA et al., 2010). 
Due to GH’s anabolic and lipolytic actions, 
use and abuse of this hormone are widespread 
among professional and unprofessional athletes 
(ANDERSON et al., 2018). On the other hand, there 
is increasing evidence that the GH-IGF1 axis could 
influence cancer risk in patients with GH deficiency 
who are treated with GH, or patients who have high 
levels of GH secretion inherently (DABROWSKA 
et al., 2014; UCHOA et al., 2013; WOLINSKI 
et al., 2017). It has been stated that both GH and 
IGF-1 have mitogenic and anti-apoptotic properties 
(BOGUSZEWSKI et al., 2016). In addition, it has 
been shown that elevated serum GH and IGF-1 
levels are associated with colorectal, breast, prostate 
and thyroid cancer (DAGDELEN et al., 2014; 
ENDOGENOUS et al., 2010). Thyroid function and 
morphology are affected by GH-IGF-1 axis. Due to 
the abundant IGF-1 receptors that are expressed 
in thyroid cells, IGF-1 is known as a proliferative 
factor for thyrocytes (MALAGUARNERA et al., 
2011; SMITH et al., 2012). The prevalence of 
nodular goiter in acromegaly is high, and the risk 
of developing cancer is increased (CURTO et al., 
2015). However, the effects of GH administration 
on thyroid tissue in athletes who abuse this hormone 
to enhance their performance and appearance are 
unknown. 
In addition, after IGF-1 binds to its receptor 
(IGF-1R) it activates two main signaling pathways: 
1) the Ras-Raf-ERK/MAPK pathway and 2) PI3K/
AKT pathway. The MAPK pathway is a classical 
intracellular signaling pathway that plays an 
essential role in cell functions, such as proliferation, 
differentiation, apoptosis, and survival, and when 
aberrantly activated, tumorigenesis (DENDULURI 
et al., 2015). Serine/threonine-protein kinase B-Raf 
(BRAF) mutation is shown to be the main cause of 
aberrant activation of the MAPK pathway in cancer. 
T1799A point BRAF mutation is the most common 
(more than 90%) of all the mutations found in the 
BRAF gene. This mutation has been illustrated to 
occur frequently in thyroid cancer (CHENG et al., 
2018). 
No data are available from the literature 
concerning the risk of developing thyroid nodules 
or tumors during GH administration. In order to 
gain more knowledge on this matter, our purpose 
was to investigate whether GH injection with 
and without resistance training can affect thyroid 
histopathology and BRAF-V600E mutation, and 
what the responses are of the circulating levels of 
IGF-1 and IGFBP-3.
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Materials and methods 
Animals. Healthy adult male brown rats 
(Rattus norvegicus 245 ± 20 g; 12 weeks old) 
were purchased from the Pasteur Research 
Center (Karaj, Iran). The rats were kept in an air-
conditioned animal room under a 12 h light:dark 
cycle, in standard environmental conditions (23 ± 
1 °C, 55 ± 5% humidity), with free access to tap 
water and a commercial dry pellet diet. The rats 
were housed in polypropylene cages lined with 
pine wood husk, which was changed every day. 
Experimental protocols were approved by the 
Ethics Review Committee of Medicine, Ferdowsi 
University of Mashhad (Ethic code: IR.MUM.
FUM.REC.1396.12). 
Experimental design. After 8 weeks of the 
experiment (i.m), thyroid tissue and blood samples 
of saline (CS), resistance training+saline (RS), 
growth hormone (2 mg/kg; Genotropin, Germany) 
(GI) and resistance training+growth hormone (2 
mg/kg) (RG) were taken to evaluate histopathology, 
the BRAF T1799A mutation of thyroid tissue, and 
circulating levels of IGF-1 and IGFBP-3. 
In the 1st week of familiarization, the rats were 
trained to climb a 1 m high ladder with 2 cm grid 
steps and an 85 ° grade, with weights tied to their 
tails. The rats were placed at the bottom of the 
ladder and were forced to climb by touching when 
necessary. The animals were trained once a day, 5 
days per week, for 8 weeks. Each training session 
consisted of 3 sets of 5 repetitions, with a one-
minute rest interval between the reps and 2 minutes 
between the sets. This method was repeated until 
either the rat finished the sets entirely or failed 
to climb after 3 stimulations. The intensity of the 
training protocol during the first week was 50% 
of each rat’s body weight. The weight that was 
carried by these rats was gradually increased at 
the beginning of each week (10% per week) ladder 
(LEE et al., 2003). 
Measurement of IGF-1 and IGFBP-3. Blood 
was obtained via the tail vein for assay of the serum 
IGF-1 and IGFBP-3. Samples were collected in the 
morning before treatment. The serum was separated 
by centrifugation (3,000 rpm for 15 min), kept at 
-20 °C and assessed by ELISA kits (Hangzhou 
Eastbiopharm, Elisa Kits, CAT.NO: CK-E30653- 
E91558), as recommended by the manufacturer.
Histopathological analysis. The thyroid was 
removed for histology and fixed in 10% buffered 
neutral formaldehyde for 72 h.
Tissue samples were processed into paraffin thin 
sections (5-7 μm), perpendicular to the longest axis 
of the, stained with hematoxylin and eosin (H&E) 
and examined by light microscopy (Olympus 
BX60, Japan) (PERRY et al., 2016).
Detecting of BRAF (T1799A) mutation. 
DNA was extracted from 100 mg of thyroid 
tissue using a NEXpreptm Tissue DNA Mini Kit 
(NEX Diagnostics, South Korea) according to 
the manufacturer’s protocol. DNA integrity was 
assessed by agarose gel electrophoresis. The purity 
and quantity of the extracted DNA were evaluated 
by Epoch microplate spectrophotometer (BioTek 
Instruments, USA). Specific primers adjacent to 
the rat’s BRAF-V600F position were designed by 
primer premier 5 (Premier Biosoft International, 
USA). Primer sequences were
5’ CACAAAATAGATCCAGACAACTGTTC-3’
for forward and 
5’ATGAAGACCTCACGGTAAAAATAGG-3’ 
for reverse primer. 
A 103 bp fragment from exon 17 of the BRAF 
gene located on chromosome 4 (Accession 
number: NC_005103.4) was amplified by standard 
polymerase chain reaction (PCR) and sequenced 
from both strands to detect the T1799A mutation. 
High-resolution melt (HRM) assay was 
conducted using the LightCycler® 96 real-time 
PCR System (Roche Life Science, Switzerland). 
Every reaction was carried out in 10 µL volume 
and contained approximately 50 ng of DNA diluted 
in 5X HOT FIREPol® EvaGreen® qPCR Mix Plus 
HRM master mix (Solis BioDyne, Estonia) and 200 
nM of each primer, with the following PCR program 
and melting conditions: 95 °C for 15 min; 40 cycles 
of 95 °C for 15S, 60 °C for 20S and 72 °C for 30S, 
followed by a high resolution melt of 70 °C - 90 °C 
(0.05 °C/S, 20 reading/ °C). Data were acquired and 
analyzed using the accompanying High-Resolution 
Melt software (Roche Life Science, Switzerland). 
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Statistical analysis. The Shapiro-Wilk Test was 
applied to examine whether measurements were 
appropriate for normal dispersion. The data were 
analyzed by SPSS software (SPSS Inc., Armonk, 
IL, USA) (Version 20). These were then subjected 
to analysis of variance (ANOVA) within and 
among groups followed by the post hoc Tukey test. 
The results were presented as Mean ± SEM (n = 7). 
Levels P<0.05 were considered significant.
Results 
Table 1 shows the results of mean serum IGF-
1, IGFBP-3 concentrations and IGF-1/IGFBP-3 
ratio. A significant decrement in the serum IGF-1 
concentration (P = 0.04) and the IGF-1/IGFBP-3 
ratio (P = 0.001) in the RS group compared to 
the other groups was observed in this study. 
However, we did not observe any changes in the 
serum IGFBP-3 concentration (P = 0.93) in the RS 
group. Furthermore, the serum IGF-1 (P = 0.001, 
P = 0.001) and IGFBP-3 concentration (P = 0.003, 
P = 0.011) and IGF-1/IGFBP-3 ratio (P = 0.001, P 
= 0.001) in GI and RG groups were significantly 
increased compared to the other groups.
The histopathological appearance of thyroid 
tissues was normal in all groups (Fig. 1). In thyroid 
tissues, microscopic examination did not show 
any significant differences in follicles, cells and 
the other tissue structures compared to the control 
group. The size of the thyroid gland and hormone 
secretions were the same in all groups. High-quality 
DNA was extracted (Fig. 2A) and a 103 bp fragment 
from exon 17 of the BRAF gene was amplified 
specifically (Fig. 2B). HRM results revealed no 
mutation in BRAF exon 17 (Fig. 3), which was 
confirmed by two-way sequencing. 
Table 1. Statistical analysis of Mean serum IGF-1, IGFBP-3 concentrations and IGF-1/IGFBP-3 ratio
Parameter Group Mean ± SD F Value P - Value
IGF-1 (ng/mL)
CS
RS
GI
RG
293.38 ± 52.5
220.62 ± ± 38.1
451.88 ± 57.9
412.25 ± 60.1
*
* #
* #
32.48 0.001
IGFBP-3 (ng/mL)
CS
RS
GI
RG
374.62 ± 66.4
388.38 ± 29.0
463.00 ± 36.0
451.62 ± 41.4 
* #
* #
7.61 0.001
IGF-1/IGFBP-3
CS
RS
GI
RG
0.78 ± 0.014
0.56 ± 0.018
0.97 ± 0.021
0.91 ± 0.016
*
*
* #
* # $
416.42 0.001
Control plus saline injection group (CS), resistance training plus saline injection group (RS), Growth hormone injection group (GI) 
and resistance training plus Growth hormone injection group (RG). * Significant difference with C group, # significant difference 
with RS group, $ significant difference with GI group. Significant difference P<0.05.
B. Roozbeh et al.: Effects of Growth hormone and training on thyroid
Vet. arhiv 90 (4), 403-412, 2020 407
Fig. 1. Histopathological features of stained thyroid tissues (X200). Control plus saline injection group (CS), 
resistance training plus saline injection group (RS), Growth hormone injection group (GI) and resistance training 
plus Growth hormone injection group.
Fig. 2. Agarose gel electrophoresis of extracted DNA from thyroid tissue of rats (A) and 103 bp PCR products (B) of 
Ratus norvegicus BRAF exon 17
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discussion
In this study, GH injection with and without 
resistance training and consequently elevated IGF-
1 levels caused no histopathological and functional 
changes on normal thyroid cells. It has been well 
established that GH and IGF-1 are associated 
with tumorigenesis (DENDULURI et al., 2015). 
Moreover, it is believed that a chronic excess of GH 
and IGF-1 plays a crucial role in the pathogenesis 
of thyroid carcinoma in acromegaly, by stimulating 
mitosis and inducing anti-apoptotic functions (WU 
et al., 2018). Additionally, acromegaly has been 
related to goiter as well as benign and malignant 
tumors (KALDRYMIDIS et al., 2016). Similarly, 
administration of recombinant GH and IGF-1 
has been found to promote tumorigenesis in vivo 
(BOGUSZEWSKI et al., 2016). The results of 
the present study showed that circulating levels 
of IGFBP-3 increased after GH injection, which 
reduced IGF-1 bioactivity. This might be a reason 
why there were no histopathological changes, since 
the time required for malignant transformation 
is inversely correlated with IGF-1 bioactivity 
(SHANMUGALINGAM et al., 2016). As far as we 
know, this study is the first to examine the chronic 
short-term effects of GH injection on normal thyroid 
tissue. However, further study is needed to evaluate 
the long-term effects of GH injection on the thyroid 
and other tissues.
Moreover, in the current study, GH injection 
and consecutive elevated IGF-1 levels resulted in 
no mutations of the BRAF exon 17 gene. It has 
been shown that the standard Sanger sequencing 
method can be applied successfully to detect 
known somatic mutations, such as in this study, 
although comprehensive sequencing may be 
required by high throughput methods (S. H. LEE 
et al., 2017). After IGF-1 binds to its tyrosine 
receptor, it activates the GTPase Ras-Raf-ERK/
MAPK pathway (DENDULURI et al., 2015). It 
has been shown that continuous and uncontrolled 
activation of the kinase pathway results in BRAF-
V600E mutation (CARONIA et al., 2011). Studies 
have reported that excessive secretion of GH and 
Fig. 3. (Top) Sequencing results and sequence alignment of number of samples with the Ratus norvegicus reference 
sequence for BRAF exon 17 (partial). The arrow shows the position of T1799A (V600E) mutation; (Bottom) 
Melting peaks of samples after HRM analysis showed no detectable mutation in the studied region.
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IGF-1 in patients with acromegaly caused thyroid 
cancer, in which activated BRAF gene mutations 
have been found (DABROWSKA et al., 2014). In 
benign and malignant human tumors, activating 
mutations of the serine-threonine kinase v-RAF 
murine sarcoma viral oncogene homolog B1 are 
prevalent and emerging as a potentially decisive 
biomarker (PAKNESHAN et al., 2013). Mutation 
of the BRAF gene is determined by the DNA-based 
method, most commonly by sequencing (CAPPER 
et al., 2011). Over 90% of BRAF mutations are 
transversions from thymine to adenine (T1799A), 
leading to a Glu for Val substitution at a mutational 
hotspot at amino acid position 600 (referred to 
as BRAF V600E). This substitution emulates the 
phosphorylation of amino acid residues T599 
and S602, and induces a change in the activation 
segment, resulting in kinase activity of BRAF and 
consequently phosphorylation of downstream 
targets (HUSSAIN et al., 2015). Exclusively high 
BRAF V600E mutation rates have been detected in 
papillary thyroid carcinoma (40-70%) (S. E. LEE 
et al., 2017). Inconsistent with a crucial role in 
thyroid cancer initiation, BRAF-V600E has been 
shown to induce transformed features in thyroid 
follicular cells in culture (MELILLO et al., 2005) 
and thyroid carcinoma formation in transgenic mice 
(IVA et al., 2018). In this study, GH administration 
increased both IGF-1 and IGFBP-3 levels, which 
decreased IGF-1 bioavailability. Additionally, in 
previous studies that reported BRAF gene mutation 
or incidence of cancers in acromegaly patients, or 
people who were administered GH, the exposure 
time to high levels of GH was longer (five years 
or more) (UCHOA et al., 2013; WOLINSKI et al., 
2017). Thus, these could be the reasons that we 
did not observe any histopathological changes or 
BRAF gene mutation in thyroid tissue. However, it 
is possible that mutation occurred in other tissues. 
Moreover, the examination of gene expression may 
help to explain more details about the effects of 
hormone administration. 
In our study, resistance training decreased 
circulating levels of IGF-1 and the IGF-1/IGFBP-3 
ratio, but circulating levels of IGFBP-3 did not 
change significantly. Over the years, the results 
of studies have demonstrated that high circulating 
levels of IGF-1 and low circulating levels of 
IGFBP-3 are associated with the risk of colorectal, 
breast, prostate and thyroid cancers (CLAYTON et 
al., 2011). Contrarily, epidemiological data show 
that physical activity is associated with a decreased 
risk in the incidence of many common cancers 
(FRIEDENREICH et al., 2010; GONCALVES 
et al., 2014; SAX et al., 2014). The decreased 
circulating levels of IGF-1 in the current study 
might be due to the anabolic role of IGF-1. It has 
been suggested that physical activity might increase 
uptake of IGF-1 into peripheral tissues and the 
central nervous system (NISHIJIMA et al., 2010). 
Studies have shown that, chronic exercise training 
causes an increase (STEIN et al., 2018), no change 
(VITIELLO et al., 1997) and a decrease (NISHIDA 
et al., 2010) in the circulating level of IGF-1, 
therefore are inconsistent. The results of previous 
studies were also inconsistent regarding the effects 
of exercise training on circulating levels of IGFBP-3 
(BORST et al., 2001; MANNERKORPI et al., 
2017). NINDL et al. (2010) showed a significant 
increase in IGFBP-3 levels after resistance exercise 
and a decrease to the baseline during the following 
13 hours. NISHIDA et al. (2010) reported that 
after 6 weeks of aerobic training, circulating levels 
of IGF-1 decreased by 9% and IGFBP-3 levels 
did not change significantly. CHICHARRO et al. 
(2001) demonstrated that 3 weeks of endurance 
competition did not alter circulating levels of 
IGFBP-3, but decreased IGF-1 levels. The disparity 
in the results of the above studies might be due to 
the exercise training models, the duration of training 
and age, and the participants’ training background 
and nutritional status (NINDL et al., 2010). 
However, GH injection with and without 
resistance training increased the circulating levels 
of IGF-1 and IGFBP-3 and IGF-1/IGFBP-3 ratio. 
Binding of IGF-1 to its receptor activates ERK/
MAPK and PI3K/AKT pathways, which stimulates 
proliferation, and inhibits apoptosis (DENDULURI 
et al., 2015). According to the role of IGF-1 as 
cell proliferator and apoptosis inhibitor, previous 
studies have indicated that increased circulating 
IGF-1 levels, decreased circulating IGFBP-3 and/
or increased IGF-1/IGFBP-3 ratio are specific 
biomarkers and might be involved in some cancers 
by increasing IGF-1 bioavailability (CLAYTON et 
al., 2011; ENDOGENOUS et al., 2010; SOUBRY 
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et al., 2012). Therefore, GH administration might 
increase the risk of cancer in the long term. Further 
study is needed to examine the effects of long term 
GH administration on thyroid and other tissues.
Conclusion 
In conclusion, short term GH administration 
with and without resistance training caused no 
changes in the histopathology of thyroid tissue, 
and no mutations were detected in the studied 
region of the BRAF gene. However, this does not 
imply that GH administration has no side effects 
on thyroid tissue or risk of cancer over a longer 
period of administration. In addition, resistance 
training decreased circulating levels of IGF-1 and 
the IGF-1/IGFBP-3 ratio, which could be noted as 
a lower risk of cancer. Nevertheless, short term GH 
administration increased circulating levels of IGF-1 
and IGF-1/IGFBP-3 ratio, which is a situation with 
a higher risk of cancer. 
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kratkotrajne primjene hormona rasta i treninga snage na histopatološke promjene tkiva štitnjače i mutaciju 
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sAžeTAK
Visoke razine hormona rasta povećavaju brzinu mitoze, ali smanjuju proces apoptoze u ciljnim organima, što 
može uzrokovati nastanak različitih tipova raka. Stoga je glavni cilj ovoga istraživanja bio utvrditi učinak kratkotrajne 
primjene hormona rasta i treninga snage na histopatološke promjene tkiva štitnjače i nalaz mutacije gena BRAF-V600E 
u mužjaka smeđeg štakora Rattus norvegicus. Ukupno 32 štakora nasumično su podijeljena u četiri skupine koje su 
ovisno o primjenjenom tretmanu označene kao CS (fiziološka otopina), RS (trening snage + fiziološka otopina), GI 
(hormone rasta, 2 mg/kg) i RG (trening snage+hormone rasta, 2 mg/kg). Nakon osam tjedana pokusa (i.m.) uzeti 
su uzorci tkiva štitnjače i uzorci krvi kako bi se procijenila histopatološka svojstva, mutacija BRAF T1799A tkiva 
štitnjače te razine cirkulacijskog IGF-1 i IGFBP-3. Trening se sastojao od toga da se štakori penju ljestvama noseći 
težinu (3 seta vježbi, 5 ponavljanja). Mikroskopska procjena tkiva štitnjače nije pokazala histopatološke promjene 
i nije bilo mutacija u promatranoj regiji sekvencija gena BRAF. Koncentracija serumskog IGF-1 bila je znakovito 
manja u skupini RS nego u ostalim skupinama (P < 0,05), no u toj skupini nije bilo znakovite promjene u koncentraciji 
serumskog IGFBP-3. Štoviše, koncentracije serumskog IGF-1 i IGFBP-3 bile su znakovito veće u skupinama GI i 
RG nego u ostalim skupinama (P < 0,05). Stoga smo zaključili da bi smanjenje koncentracije serumskog IGF-1 i 
IGF-1/IGFBP-3 nakon treninga snage moglo smanjiti rizik od raka. Osim toga kratkotrajna primjena hormona rasta, 
s treningom snage kao i bez njega, mogla bi povećati rizik od raka povećavajući koncentracije serumskog IGF-1 i 
IGF-1/IGFBP-3 u mužjaka štakora. 
Ključne riječi: gen BRAF (T1799A); rak; hormon rasta; trening snage; štitnjača_____________________________________________________________________________________________
